“It may be the holy grail on this because it was just studied in phase two trials and it literally stopped the virus in its tracks,” Dr. Marc Siegel, a medical director of Doctor Radio at NYU Langone Medical Center explained on Fox News on Sunday. “And there wasn’t any virus found in the patients that were studied.”
First-stage testing of the experimental COVID-19 pill called Molnupiravir, by Merck and Ridgeback Biotherapeutics, showed promising signs of effectiveness in reducing the virus in patients. The drug would function as an at-home, five-day treatment, similar to Tamiflu, to stop the virus from reproducing before causing major damage. Siegel said the therapeutic could come to market in as little as four to five months.
— Merck (@Merck) March 6, 2021